Home › Research › Topics › peptide-1-glp-1
peptide-1-glp-1
4 studies tagged peptide-1-glp-1, dated 2008-03-20 to 2024-10-21. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders 2024-10-21
- The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity 2019-05-01
- [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?] 2014-12-01
Studies
4 studies carry this tag.
Date range
2008 to 2024
Top journals
- Cureus 1
- Neurochemical research 1
- Revista de neurologia 1
- The International journal of neuroscience 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Glucagon-like peptide-1 (GLP-1) agonists have emerged as a groundbreaking class of medications for managing type 2 diabetes and associated metabolic disorders.
-
Diabetes mellitus (DM) is one of the most common metabolic disorders characterized by hyperglycemia due to insufficiency of insulin and/or insulin resistance.
-
The GLP-1 analogs have neuroprotective properties.
-
Glucagon-like peptide-1 (GLP-1) is a glucoincretin hormone most intensively studied for its actions on insulin secreting beta-cells.